Profil
F.
Andrew Dorr served as the Chief Medical Officer at Ionis Pharmaceuticals, Inc. from 1996 to 2003.
He then worked as the Chief Operating Officer at Salmedix, Inc. in 2004.
Later, he became the Chief Medical Officer at Spyre Therapeutics, Inc. Dr. Dorr received his undergraduate degree from Davidson College and his doctorate from The University of North Carolina at Charlotte.
Ehemalige bekannte Positionen von F. Andrew Dorr
Unternehmen | Position | Ende |
---|---|---|
SPYRE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 21.04.2017 |
Salmedix, Inc.
Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Geschäftsführer | 01.08.2004 |
IONIS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 |
Ausbildung von F. Andrew Dorr
Davidson College | Undergraduate Degree |
The University of North Carolina at Charlotte | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SPYRE THERAPEUTICS, INC. | Health Technology |
IONIS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Salmedix, Inc.
Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Health Technology |